Milestone Pharmaceuticals Inc.
etripamil
atrial fibrillation with rapid ventricular rate (AFib-RVR)
Countdown
358days
Phase 3 readout · ~ Jun 30, 2027 estimated
What's at stake
Phase 3 trial results for etripamil in atrial fibrillation with rapid ventricular rate (AFib-RVR) are due ~ Jun 30, 2027. A clean hit validates the program; a miss can gap the stock down hard.
Primary source
· SEC 8-K
verified 15h ago
“A European decision on approval is expected by the first half of 2027.”